Using honey bee colonies to monitor phenotypic and genotypic resistance to colistin

Ilaria Resci1, Laura Zavatta2, Silvia Piva3

  • 1Research Centre for Agriculture and Environment (CREA-AA), Council for Agricultural Research and Agricultural Economics Analysis, Bologna, Italy; Department of Veterinary Sciences, University of Bologna, Ozzano Dell'Emilia (BO), Italy; Department of Veterinary Sciences, University of Pisa, Pisa, Italy.

Chemosphere
|June 29, 2024
PubMed

Insights

Honey bees effectively bioindicate colistin resistance in environmental bacteria. Mobile colistin resistance (mcr) genes were detected in over half of Gram-negative bacteria isolated from Italian honey bees, highlighting environmental dissemination.

Area of Science:

  • Microbiology
  • Environmental Science
  • One Health

Background:

  • Colistin is crucial for treating multidrug-resistant Gram-negative bacterial infections.
  • Mobile colistin resistance (mcr) genes on plasmids facilitate bacterial resistance spread.
  • Limited research exists on the environmental dissemination of mcr genes.

Purpose of the Study:

  • To assess colistin resistance in Gram-negative bacteria from honey bees.
  • To identify the prevalence and distribution of mcr genes in environmental bacteria.
  • To evaluate honey bees as bioindicators for antimicrobial resistance.

Main Methods:

  • Environmental Gram-negative bacteria were isolated from foraging honey bees across 33 colonies in Italy.
  • Phenotypic colistin resistance was determined using minimum inhibitory concentration (MIC) assays.
  • Genotypic identification of nine mcr genes was performed using multiplex PCR assays.

Main Results:

  • 68.5% of bacterial isolates exhibited colistin resistance, with Enterobacter spp. showing the highest rates (84.5%).
  • Mobile colistin resistance (mcr) genes were detected in 53.3% of isolates.
  • The mcr5 gene was most prevalent (35.3%), found across seven provinces, while mcr4 was least common (4.8%).

Conclusions:

  • Honey bees serve as effective bioindicators for detecting colistin resistance genes in environmental bacteria.
  • This study demonstrates the feasibility of monitoring environmental dissemination of mcr genes.
  • Findings support a One Health approach for understanding antimicrobial resistance spread and public health implications.

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121